Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. AMZN
2. INTC
3. PINS
4. COIN
5. RDDT
6. FSLR
7. FND
8. SNDK
9. DASH
10. RBLX

Go back to Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

Cyclacel Pharma (CYCC) Misses Q4 EPS by 83c

February 25, 2021 5:19 PM EST

Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($1.34), $0.83 worse than the analyst estimate of ($0.51).

During 2020 we have reported on fadraciclibs oral bioavailability and evidence of durable anticancer activity, said Spiro Rombotis, President and Chief Executive Officer. Independent evidence supporting the rationale for... More